Molecular alterations in meningiomas: Literature review

Imagem de Miniatura
Arquivos
art_PEREIRA_Molecular_alterations_in_meningiomas_Literature_review_2019.PDF (519.66 KB)
Citações na Scopus
25
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
Citação
CLINICAL NEUROLOGY AND NEUROSURGERY, v.176, p.89-96, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Meningiomas, tumors that originate from meningothelial cells, account for approximately 30% of all new diagnoses of central nervous system neoplasms. According to the 2016 WHO classification of central nervous system tumors meningiomas are classified into three grades: I, II, and III. Past studies have shown that the risk of meningiomas recurrence is strongly correlated with the molecular profile of the tumor. Extensive whole-exome or whole-genome sequencing has provided a large body of information about the mutational landscape of meningiomas. However, such a stratification of meningiomas based on mutational analysis alone has been proven not to satisfy the clinical need for distinction between patients who need (or do not need) an adjuvant treatment. Combined analysis of exome, transcriptome, methylome and future approaches for epigenetic aspects in meningiomas may allow researchers to unveil a more comprehensive understanding of tumor progression mechanisms and, consequently, a more personalized clinical approach for patients with meningioma. A better understanding of the genetics and clinical behavior of high-grade meningiomas is mandatory in order to better design future clinical trials. By studying the mechanisms underlying these new tumorigenesis pathways, we should be able to offer personalized chemotherapy to patients with surgery and radiation-refractory meningiomas in the near future. The purpose of this article is to accurately bring the compilation of this information, for a greater understanding of the subject.
Palavras-chave
Meningioma, Molecular, Mutation, Genetics
URI
https://observatorio.fm.usp.br/handle/OPI/30863
Referências
  1. Abedalthagafi M, 2016, NEURO-ONCOLOGY, V18, P649, DOI 10.1093/neuonc/nov316
  2. Barresi V, 2010, NEUROPATHOLOGY, V30, P537, DOI 10.1111/j.1440-1789.2010.01105.x
  3. Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013
  4. Bi WL, 2016, J NEUROSURG, V125, P525, DOI 10.3171/2015.6.JNS15591
  5. Bianchi K, 2009, MOL CELL, V36, P736, DOI 10.1016/j.molcel.2009.11.029
  6. Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170
  7. BOLGER GB, 1985, NEW ENGL J MED, V312, P564, DOI 10.1056/NEJM198502283120907
  8. Bourboulia D, 2010, SEMIN CANCER BIOL, V20, P161, DOI 10.1016/j.semcancer.2010.05.002
  9. Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086
  10. Boyd C, 2008, CLIN GENET, V74, P358, DOI 10.1111/j.1399-0004.2008.01060.x
  11. Brastianos PK, 2013, NAT GENET, V45, P285, DOI 10.1038/ng.2526
  12. Brembeck FH, 2000, J BIOL CHEM, V275, P28230
  13. Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
  14. Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
  15. Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933
  16. Cazals V, 1999, BBA-MOL CELL RES, V1448, P349, DOI 10.1016/S0167-4889(98)00095-0
  17. Christov C, 1999, ACTA NEUROPATHOL, V98, P414, DOI 10.1007/s004010051102
  18. Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009
  19. Clarke VE, 2016, NAT GENET, V48, P1253, DOI 10.1038/ng.3651
  20. de Almeida AN, 2017, WORLD NEUROSURG, V102, P139, DOI 10.1016/j.wneu.2017.03.009
  21. DUMANSKI JP, 1990, CANCER RES, V50, P5863
  22. DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275
  23. Dziuk TW, 1998, J NEURO-ONCOL, V37, P177, DOI 10.1023/A:1005853720926
  24. Evans DGR, 2000, J MED GENET, V37, P897, DOI 10.1136/jmg.37.12.897
  25. Evans JJ, 2001, J NEUROSURG, V94, P111, DOI 10.3171/jns.2001.94.1.0111
  26. Evans LT, 2015, J NEUROSURG-PEDIATR, V16, P296, DOI 10.3171/2015.3.PEDS14417
  27. Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
  28. FONTAINE B, 1991, ANN NY ACAD SCI, V615, P338
  29. Galani V, 2017, CLIN NEUROL NEUROSUR, V158, P119, DOI 10.1016/j.clineuro.2017.05.002
  30. Goutagny S, 2014, BRAIN PATHOL, V24, P184, DOI 10.1111/bpa.12110
  31. GRIFFIN CA, 1994, CANCER GENET CYTOGEN, V78, P46, DOI 10.1016/0165-4608(94)90045-0
  32. Hadfield KD, 2008, J MED GENET, V45, P332, DOI 10.1136/jmg.2007.056499
  33. Hadfield KD, 2010, ONCOGENE, V29, P6216, DOI 10.1038/onc.2010.363
  34. Hadfield KD, 2010, J MED GENET, V47, P567, DOI 10.1136/jmg.2009.075721
  35. Hale AT, 2018, J CLIN NEUROSCI, V48, P71, DOI 10.1016/j.jocn.2017.11.013
  36. Hampson L, 2001, Hematol J, V2, P150, DOI 10.1038/sj.thj.6200102
  37. HARN HJ, 1994, BIOCHEM MOL BIOL INT, V33, P743
  38. He SH, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.10.FOCUS13360
  39. Huang Q, 2013, INT J MED SCI, V10, P276, DOI 10.7150/ijms.5185
  40. Hug EB, 2000, J NEURO-ONCOL, V48, P151, DOI 10.1023/A:1006434124794
  41. Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304
  42. Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333
  43. Juratli TA, 2017, ONCOTARGET, V8, P109228, DOI 10.18632/oncotarget.22650
  44. Karczmarski J, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-24
  45. Katar S, 2017, CLIN NEUROL NEUROSUR, V156, P66, DOI 10.1016/j.clineuro.2017.03.016
  46. Katz LM, 2018, ACTA NEUROPATHOL, V135, P955, DOI 10.1007/s00401-018-1844-9
  47. Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
  48. Kros J, 2001, J PATHOL, V194, P367, DOI 10.1002/path.909
  49. Kshettry VR, 2015, NEURO-ONCOLOGY, V17, P1166, DOI 10.1093/neuonc/nov069
  50. Lang CH, 1999, AM J PHYSIOL-GASTR L, V276, pG719
  51. LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583
  52. LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008
  53. Lee Y, 2010, BRAIN PATHOL, V20, P751, DOI 10.1111/j.1750-3639.2009.00356.x
  54. Linda W, 2016, NEUROSURG CLIN N AM, V27, P167, DOI 10.1016/j.nec.2015.11.009
  55. Liu LP, 2010, CANCER INVEST, V28, P443, DOI 10.3109/07357900903405959
  56. Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
  57. Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
  58. Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2
  59. McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009
  60. MEESE E, 1987, HUM GENET, V77, P349, DOI 10.1007/BF00291425
  61. Metkar SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8
  62. Morita Y, 2005, MOL BIOL CELL, V16, P5433, DOI 10.1091/mbc.E05-08-0731
  63. Nanda A, 2016, J CLIN NEUROSCI, V31, P112, DOI 10.1016/j.jocn.2016.02.021
  64. Nekrasov M, 2007, EMBO J, V26, P4078, DOI 10.1038/sj.emboj.7601837
  65. Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079
  66. Nishikawa R, 1998, ACTA NEUROPATHOL, V96, P453, DOI 10.1007/s004010050919
  67. Otsuka S, 2004, J NEURO-ONCOL, V70, P349, DOI 10.1007/s11060-004-9164-4
  68. Pecina-Slaus N, 2008, J NEURO-ONCOL, V87, P63, DOI 10.1007/s11060-007-9500-6
  69. Pecina-Slaus N, 2016, ANTICANCER RES, V36, P4583, DOI 10.21873/anticanres.11007
  70. Pecina-Slaus N, 2016, INT J EXP PATHOL, V97, P159, DOI 10.1111/iep.12186
  71. Pecina-Slaus N, 2010, J CANCER RES CLIN, V136, P695, DOI 10.1007/s00432-009-0708-z
  72. PecinaSlaus N., 2016, CANCERS BASEL, V8
  73. Pereira B. J. A., 2017, WORLD NEUROSURG
  74. Perez-Magan E, 2012, J NEUROPATH EXP NEUR, V71, P882, DOI 10.1097/NEN.0b013e31826bf704
  75. Perry A, 1999, CANCER, V85, P2046, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M
  76. Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872
  77. PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393
  78. Peyre M., 2017, NEUROONCOL
  79. Pham MH, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1117
  80. Pietsch T, 1997, ACTA NEUROPATHOL, V93, P109, DOI 10.1007/s004010050591
  81. Pistolesi S, 2004, NEUROPATH APPL NEURO, V30, P118, DOI 10.1111/j.1365-2990.2003.0516.x
  82. Pistolesi S, 2002, J NEURO-ONCOL, V60, P159, DOI 10.1023/A:1020624119944
  83. Preusser M., 2018, NAT REV NEUROL
  84. Raffalli-Ebezant H, 2015, CHILD NERV SYST, V31, P441, DOI 10.1007/s00381-014-2558-5
  85. Ragel Brian T, 2005, Neurosurg Focus, V19, pE9
  86. Reszec J, 2015, BIOMED RES INT, DOI 10.1155/2015/646853
  87. Reuss DE, 2013, ACTA NEUROPATHOL, V125, P351, DOI 10.1007/s00401-013-1093-x
  88. Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1
  89. Rosenberg LA, 2009, INT J RADIAT ONCOL, V74, P427, DOI 10.1016/j.ijrobp.2008.08.018
  90. Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780
  91. Roy R, 2006, EXP CELL RES, V312, P608, DOI 10.1016/j.yexcr.2005.11.022
  92. Ruiz J, 2015, CLIN NEUROPATHOL, V34, P322, DOI 10.5414/NP300860
  93. RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180
  94. Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9
  95. Sahm F, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv377
  96. Sahm F, 2013, ACTA NEUROPATHOL, V126, P757, DOI 10.1007/s00401-013-1187-5
  97. Saifudeen Z, 2005, AM J PHYSIOL-RENAL, V288, pF899, DOI 10.1152/ajprenal.00370.2004
  98. Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09
  99. Schaefer IM, 2016, MODERN PATHOL, V29, P4, DOI 10.1038/modpathol.2015.134
  100. Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
  101. Schmitz U, 2001, BRIT J CANCER, V84, P199, DOI 10.1054/bjoc.2000.1583
  102. Schuetz A, 2011, CELL MOL LIFE SCI, V68, P3121, DOI 10.1007/s00018-010-0618-x
  103. Sestini R, 2008, HUM MUTAT, V29, P227, DOI 10.1002/humu.20679
  104. Sharma S, 2015, PROTEOMICS, V15, P394, DOI 10.1002/pmic.201400328
  105. Smith MJ, 2014, J PATHOL, V234, P436, DOI 10.1002/path.4427
  106. Smith MJ, 2013, NAT GENET, V45, P295, DOI 10.1038/ng.2552
  107. Smith MJ, 2012, NEUROGENETICS, V13, P141, DOI 10.1007/s10048-012-0319-8
  108. Sughrue ME, 2010, J NEUROSURG, V113, P202, DOI 10.3171/2010.1.JNS091114
  109. Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273
  110. Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
  111. Tang HL, 2017, J MOL CELL BIOL, V9, P315, DOI 10.1093/jmcb/mjx023
  112. TauziedeEspariat A., 2017, BRAIN PATHOL
  113. Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879
  114. Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639
  115. Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
  116. Wang MM, 2015, BIOCHEM BIOPH RES CO, V460, P354, DOI 10.1016/j.bbrc.2015.03.038
  117. Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x
  118. Watson MA, 2002, AM J PATHOL, V161, P665, DOI 10.1016/S0002-9440(10)64222-8
  119. Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
  120. Whittle IR, 2004, LANCET, V363, P1535, DOI 10.1016/S0140-6736(04)16153-9
  121. WINTZERITH M, 1992, NUCLEIC ACIDS RES, V20, P910, DOI 10.1093/nar/20.4.910
  122. Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108
  123. Xavier GM, 2016, DEV BIOL, V415, P198, DOI 10.1016/j.ydbio.2016.02.009
  124. Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200
  125. Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
  126. Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200
  127. Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
  128. Yuzawa S, 2016, BRAIN TUMOR PATHOL, V33, P237, DOI 10.1007/s10014-016-0271-7
  129. Zhang X, 2014, DISCOV MED, V18, P301
  130. Zhu CL, 2015, MOL MED REP, V11, P3647, DOI 10.3892/mmr.2014.3134
  131. Zotti T, 2011, J BIOL CHEM, V286, P22924, DOI 10.1074/jbc.M110.215426

Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/15
Artigos e Materiais de Revistas Científicas - ODS/03